ExpreS2ion’s core platform patent allowed in India
Hørsholm, Denmark, December 28, 2017 – Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in India and will be granted with expiry June 12, 2029.“Obtaining a strong patent protection in India, one of the world’s largest markets for vaccine technology, is an important step towards our goal to have the ExpreS2 platform protected in all major markets and consolidate our position as a global player. We